Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The amyloid hypothesis states that a variety of neurotoxic β-amyloid (Aβ) species contribute to the pathogenesis of Alzheimer's disease. Accordingly, a key determinant of disease onset and progression is the appropriate balance between Aβ production and clearance. Enzymes responsible for the degradation of Aβ are not well understood, and, thus far, it has not been possible to enhance Aβ catabolism by pharmacological manipulation. We provide evidence that Aβ catabolism is increased after inhibition of plasminogen activator inhibitor-1 (PAI-1) and may constitute a viable therapeutic approach for lowering brain Aβ levels. PAI-1 inhibits the activity of tissue plasminogen activator (tPA), an enzyme that cleaves plasminogen to generate plasmin, a protease that degrades Aβ oligomers and monomers. Because tPA, plasminogen and PAI-1 are expressed in the brain, we tested the hypothesis that inhibitors of PAI-1 will enhance the proteolytic clearance of brain Aβ. Our data demonstrate that PAI-1 inhibitors augment the activity of tPA and plasmin in hippocampus, significantly lower plasma and brain Aβ levels, restore long-term potentiation deficits in hippocampal slices from transgenic Aβ-producing mice, and reverse cognitive deficits in these mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 2×
“Of particular relevance, PAI-1 expression is increased in the vicinity of amyloid deposits in brain (11) and is elevated at sites of inflammatory response in AD patients (21).”
BackgroundEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Self-citationNeuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin
Chen, Z.-L., & Strickland, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80483-3 · Cited by 632 · cited 1×
“For example, increased synthesis of tPA leading to neuronal death after seizure or stroke (42, 43) and the subsequent generation of plasmin resulting in degradation of the extracellular matrix (42, 44) are reported.”
BackgroundLing, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224 · cited 1×
“Neurodegeneration and other pathophysiological conditions have also been associated with overexpression (38, 39) or with exogenously added components of the tPA/plasmin cascade (28, 40, 41).”
BackgroundMelchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202
Cited by
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., Pastores, G. M., Rubinsztein, D. C., Nixon, R. A., Duchen, M. R., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.109 · Cited by 558
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Metadata
- Authors
- Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., Zhou, H., Atchison, K., Wagner, E., Zaleska, M. M., Das, I., Arias, R. L., Bard, J., Riddell, D., Gardell, S. J., Abou-Gharbia, M., Robichaud, A., Magolda, R., Vlasuk, G. P., Bjornsson, T., Reinhart, P. H., & Pangalos, M. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-06-24
- Volume
- 105
- Issue
- 25
- Pages
- 8754-8759
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2132558186
- Cited by
- 146
- References
- 8
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade. https://app.cochat.ai/papers/10.1073/pnas.0710823105
- The paper
- Jacobsen, J. S., Comery, T. A., Martone, R. L., Elokdah, H., Crandall, D. L., Oganesian, A., Aschmies, S., Kirksey, Y., Gonzales, C., Xu, J., Zhou, H., Atchison, K., Wagner, E., Zaleska, M. M., Das, I., Arias, R. L., Bard, J., Riddell, D., Gardell, S. J., . . . Pangalos, M. N. (2008). Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0710823105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.